Core Points - Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing next-generation cancer therapies with improved efficacy and safety [1][3] - The company will participate in the 2025 BIO CEO & Investor Conference on February 10-11, 2025, at the New York Marriott Marquis [1] - Management will present a corporate overview on February 11 at 10:00 a.m. Eastern time and will hold one-on-one meetings with registered investors throughout the conference [2] Company Overview - Processa's strategy involves modifying existing FDA-approved oncology therapies to enhance their metabolism and distribution while maintaining their cancer-killing mechanisms [3] - The company aims to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path [3]
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference